300858 科拓生物
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)1.1295.3575.4518.25011.531
总资产报酬率 ROA (%)1.0575.0655.1917.76010.739
投入资产回报率 ROIC (%)1.1145.2685.3618.08511.344

边际利润分析
销售毛利率 (%)50.33258.25254.58251.97550.313
营业利润率 (%)32.64036.15134.28734.55834.201
息税前利润/营业总收入 (%)26.24927.85826.26233.17532.338
净利润/营业总收入 (%)26.19431.16231.23929.76730.042

收益指标分析
经营活动净收益/利润总额(%)83.16283.94387.84889.41177.507
价值变动净收益/利润总额(%)5.1245.1387.2377.43310.599
营业外收支净额/利润总额(%)0.091-0.583-0.549-1.529-0.427

偿债能力分析
流动比率 (X)11.4069.92516.29615.56012.046
速动比率 (X)10.9529.44115.62714.96311.200
资产负债率 (%)6.2846.5794.2595.3087.046
带息债务/全部投入资本 (%)-0.382-0.0800.7370.9661.715
股东权益/带息债务 (%)-25,868.843-122,902.59313,323.43710,189.1205,668.954
股东权益/负债合计 (%)1,491.2241,419.9552,247.7411,783.7981,319.193
利息保障倍数 (X)-4.088-3.446-3.350-38.431-18.825

营运能力分析
应收账款周转天数 (天)72.62472.447101.453106.466115.992
存货周转天数 (天)104.371122.204119.403105.36796.953